[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Subdural Haematoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?

May 2024 | 134 pages | ID: S656ED4BA00CEN
IMARC Group

US$ 6,499.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The 7 major subdural haematoma markets are expected to exhibit a CAGR of 3.61% during 2024-2034.

The subdural haematoma market has been comprehensively analyzed in IMARC’s new report titled “Subdural Haematoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Subdural haematoma refers to an accumulation of blood between the dura, the outermost layer of the brain, and the next layer, called the arachnoid. The bleeding rapidly occupies the brain region, thereby compressing brain tissue. This frequently results in brain damage and might even be fatal. The symptoms of subdural haematoma generally fluctuate depending on the pace of the bleeding. Occasionally, the symptoms appear straight away, and sometimes they may take up to two weeks to occur. These indications include drowsiness and disorientation, convulsions, vomiting, speech and cognitive impairments, vision disturbances, losing and regaining consciousness, numbness or weakness that may come and go, and extreme fatigue. A doctor usually performs a computed tomography (CT) or magnetic resonance imaging (MRI) scan to detect a subdural haematoma. Additional tests can also be requested, including a blood test to examine any complications with the clotting and further blood tests to eliminate any other possible reason for the patient's apparent symptoms. A CT angiography may also be carried out to confirm the condition.

The rising incidences of risk factors associated with subdural haematoma, such as the increasing number of head injuries and the growing alcohol abuse, are primarily driving the subdural haematoma market. In addition to this, the escalating utilization of aspirin, anti-inflammatory drugs such as ibuprofen, and anticoagulant medications is also bolstering the market growth. Moreover, the expanding geriatric population, who are more susceptible to brain shrinkage that occurs with aging, is further acting as a significant growth-inducing factor. Subdural haematoma results from bleeding originating from bridging veins, which are prone to injury following acceleration/deceleration movement of the brain. Besides this, the widespread adoption of contrast-enhanced MRI as it can easily detect neomembranes, thick and extensive membranes, and solid clots is also augmenting the global market. Additionally, the emerging popularity of burr-hole evacuation for treating uncomplicated subdural haematoma, which involves drilling one or more small holes in the skull and inserting a flexible rubber tube to drain the clot, is further creating a positive outlook for the market. Apart from this, several key players are making significant investments to better understand the merits and limitations of different surgical techniques, which could eventually help improve the prognosis. This, in turn, is expected to drive the global subdural haematoma market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the subdural haematoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for subdural haematoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the subdural haematoma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the subdural haematoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the subdural haematoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current subdural haematoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights

How has the subdural haematoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the subdural haematoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the subdural haematoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the size of the subdural haematoma patient pool (?2018-2023?) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of subdural haematoma?
What will be the growth rate of patients across the seven major markets?

Subdural Haematoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for subdural haematoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the subdural haematoma market?
1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SUBDURAL HAEMATOMA - INTRODUCTION

4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence

5 SUBDURAL HAEMATOMA - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 SUBDURAL HAEMATOMA - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
  7.2.1 Epidemiology Scenario (?2018-2023?)
  7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
  7.3.1 Epidemiology Scenario (?2018-2023?)
  7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
  7.4.1 Epidemiology Scenario (?2018-2023?)
  7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
  7.5.1 Epidemiology Scenario (?2018-2023?)
  7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
  7.6.1 Epidemiology Scenario (?2018-2023?)
  7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
  7.7.1 Epidemiology Scenario (?2018-2023?)
  7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
  7.8.1 Epidemiology Scenario (?2018-2023?)
  7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
  7.9.1 Epidemiology Scenario (?2018-2023?)
  7.9.2 Epidemiology Forecast (?2024-2034?)

8 SUBDURAL HAEMATOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 SUBDURAL HAEMATOMA - UNMET NEEDS

10 SUBDURAL HAEMATOMA - KEY ENDPOINTS OF TREATMENT

11 SUBDURAL HAEMATOMA - MARKETED PRODUCTS

11.1 List of Subdural Haematoma Marketed Drugs Across the Top 7 Markets
  11.1.1 Drug Name – Company Name
    11.1.1.1 Drug Overview
    11.1.1.2 Mechanism of Action
    11.1.1.3 Regulatory Status
    11.1.1.4 Clinical Trial Results
    11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.

12 SUBDURAL HAEMATOMA - PIPELINE DRUGS

12.1 List of Subdural Haematoma Pipeline Drugs Across the Top 7 Markets
  12.1.1 Drug Name – Company Name
    12.1.1.1 Drug Overview
    12.1.1.2 Mechanism of Action
    12.1.1.3 Clinical Trial Results
    12.1.1.4 Safety and Efficacy
    12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.

13. SUBDURAL HAEMATOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 SUBDURAL HAEMATOMA - MARKET SCENARIO

14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
  14.2.1 Subdural Haematoma - Market Size
    14.2.1.1 Market Size (?2018-2023?)
    14.2.1.2 Market Forecast (?2024-2034?)
  14.2.2 Subdural Haematoma - Market Size by Therapies
    14.2.2.1 Market Size by Therapies (?2018-2023?)
    14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
  14.3.1 Subdural Haematoma - Market Size
    14.3.1.1 Market Size (?2018-2023?)
    14.3.1.2 Market Forecast (?2024-2034?)
  14.3.2 Subdural Haematoma - Market Size by Therapies
    14.3.2.1 Market Size by Therapies (?2018-2023?)
    14.3.2.2 Market Forecast by Therapies (?2024-2034?)
  14.3.3 Subdural Haematoma - Access and Reimbursement Overview
14.4 Market Scenario - Germany
  14.4.1 Subdural Haematoma - Market Size
    14.4.1.1 Market Size (?2018-2023?)
    14.4.1.2 Market Forecast (?2024-2034?)
  14.4.2 Subdural Haematoma - Market Size by Therapies
    14.4.2.1 Market Size by Therapies (?2018-2023?)
    14.4.2.2 Market Forecast by Therapies (?2024-2034?)
  14.4.3 Subdural Haematoma - Access and Reimbursement Overview
14.5 Market Scenario - France
  14.5.1 Subdural Haematoma - Market Size
    14.5.1.1 Market Size (?2018-2023?)
    14.5.1.2 Market Forecast (?2024-2034?)
  14.5.2 Subdural Haematoma - Market Size by Therapies
    14.5.2.1 Market Size by Therapies (?2018-2023?)
    14.5.2.2 Market Forecast by Therapies (?2024-2034?)
  14.5.3 Subdural Haematoma - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
  14.6.1 Subdural Haematoma - Market Size
    14.6.1.1 Market Size (?2018-2023?)
    14.6.1.2 Market Forecast (?2024-2034?)
  14.6.2 Subdural Haematoma - Market Size by Therapies
    14.6.2.1 Market Size by Therapies (?2018-2023?)
    14.6.2.2 Market Forecast by Therapies (?2024-2034?)
  14.6.3 Subdural Haematoma - Access and Reimbursement Overview
14.7 Market Scenario - Italy
  14.7.1 Subdural Haematoma - Market Size
    14.7.1.1 Market Size (?2018-2023?)
    14.7.1.2 Market Forecast (?2024-2034?)
  14.7.2 Subdural Haematoma - Market Size by Therapies
    14.7.2.1 Market Size by Therapies (?2018-2023?)
    14.7.2.2 Market Forecast by Therapies (?2024-2034?)
  14.7.3 Subdural Haematoma - Access and Reimbursement Overview
14.8 Market Scenario - Spain
  14.8.1 Subdural Haematoma - Market Size
    14.8.1.1 Market Size (?2018-2023?)
    14.8.1.2 Market Forecast (?2024-2034?)
  14.8.2 Subdural Haematoma - Market Size by Therapies
    14.8.2.1 Market Size by Therapies (?2018-2023?)
    14.8.2.2 Market Forecast by Therapies (?2024-2034?)
  14.8.3 Subdural Haematoma - Access and Reimbursement Overview
14.9 Market Scenario - Japan
  14.9.1 Subdural Haematoma - Market Size
    14.9.1.1 Market Size (?2018-2023?)
    14.9.1.2 Market Forecast (?2024-2034?)
  14.9.2 Subdural Haematoma - Market Size by Therapies
    14.9.2.1 Market Size by Therapies (?2018-2023?)
    14.9.2.2 Market Forecast by Therapies (?2024-2034?)
  14.9.3 Subdural Haematoma - Access and Reimbursement Overview

15 SUBDURAL HAEMATOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

16 SUBDURAL HAEMATOMA MARKET - SWOT ANALYSIS

16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 APPENDIX


More Publications